Takeaway
- Full-dose apixaban was not superior to standard of care (SOC) antithrombotic treatment after successful trans-aortic valve implantation (TAVI) for aortic stenosis.
- In patients without an indication for oral anticoagulant (OAC), apixaban use was associated with higher noncardiovascular mortality vs antiplatelet therapy (APT).
Why this matters
- Frequent thrombotic and bleeding events,...
